Literature DB >> 8582956

The growth hormone response to growth hormone-releasing hormone is blunted in polycystic ovary syndrome: relationship with obesity and hyperinsulinaemia.

A Lanzone1, P Villa, A M Fulghesu, V Pavone, A Caruso, S Mancuso.   

Abstract

This study was designed to investigate the growth hormone (GH) secretory response to the growth hormone-releasing hormone (GHRH) test in women with polycystic ovary syndrome (PCOS). A total of 25 patients with PCOS (13 obese and 12 non-obese) and 15 normal ovulatory women (seven obese and eight non-obese) were included in this study. In the follicular phase patients were subjected to an oral glucose tolerance test (OGTT); 2 days later they underwent a GHRH test. Basal plasma concentrations of gonadotrophins, steroids and sex hormone-binding globulin were measured. Insulin and GH were assayed under the OGTT and GHRH test respectively. Based on the insulin response to OGTT in the PCOS group, nine patients were classified as normoinsulinaemic and 16 as hyperinsulinaemic; none of the patients of the control group had a hyperinsulinaemic response to OGTT. Obese patients showed a trend towards a lower GH response to GHRH. Moreover, hyperinsulinaemic patients showed a significantly (P < 0.05) lower area under the curve for secretion of GH (AUC-GH) as compared to normo-insulinaemic patients. All PCOS patients exhibited a markedly decreased response of GH to GHRH compared with the control population. Obese and hyperinsulinaemic PCOS patients were both found to have a lower response of GH to GHRH than all other groups. Despite the fact that obesity and hyperinsulinaemia have an additive influence on the impairment of GH secretion, our results suggest that other factors may also negatively affect GH secretion in PCOS.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8582956     DOI: 10.1093/oxfordjournals.humrep.a136150

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  5 in total

1.  GH release after GHRH plus arginine administration in obese and overweight women with polycystic ovary syndrome.

Authors:  F Orio; S Palomba; A Colao; T Russo; C Dentico; L Tauchmanovà; S Savastano; C Nappi; C Sultan; F Zullo; G Lombardi
Journal:  J Endocrinol Invest       Date:  2003-02       Impact factor: 4.256

2.  Insulin and GH secretion in adolescent girls with irregular cycles: polycystic vs multifollicular ovaries.

Authors:  P Villa; A Rossodivita; A M Fulghesu; F Cucinelli; A Barini; R Apa; C Belosi; A Lanzone
Journal:  J Endocrinol Invest       Date:  2003-04       Impact factor: 4.256

3.  Growth-hormone response to combined stimulation with GHRH plus GH-releasing peptide-6 in obese patients with polycystic ovary syndrome before and after short-term fasting.

Authors:  D Micić; M Sumarac-Dumanović; Dj Macut; A Kendereski; S Zoric; V Popović; G Cvijović; C Dieguez; F F Casanueva
Journal:  J Endocrinol Invest       Date:  2003-04       Impact factor: 4.256

4.  Effects of ghrelin administration on endocrine and metabolic parameters in obese women with polycystic ovary syndrome.

Authors:  A Fusco; A Bianchi; A Mancini; D Milardi; A Giampietro; V Cimino; T Porcelli; D Romualdi; M Guido; A Lanzone; A Pontecorvi; L De Marinis
Journal:  J Endocrinol Invest       Date:  2007-12       Impact factor: 4.256

Review 5.  Oxidative Stress and Low-Grade Inflammation in Polycystic Ovary Syndrome: Controversies and New Insights.

Authors:  Antonio Mancini; Carmine Bruno; Edoardo Vergani; Claudia d'Abate; Elena Giacchi; Andrea Silvestrini
Journal:  Int J Mol Sci       Date:  2021-02-07       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.